TKTX Transkaryotic Therapies (MM)

TKT to Present at Banc of America's 2004 Health Care Conference CAMBRIDGE, Mass., May 13 /PRNewswire-FirstCall/ -- Transkaryotic Therapies, Inc. today announced that the company will present at Banc of America's 2004 Health Care Conference being held May 19-21 in Las Vegas, Nevada. Michael J. Astrue, President and Chief Executive Officer will present an overview of TKT's business activities at 11:20 a.m. Pacific Time on Thursday, May 20, 2004. A live audio webcast of this presentation will be available at http://www.tktx.com/ on TKT's Investor Information website under the Events category. A replay will be available until June 3, 2004. About TKT Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily focused on researching, developing and commercializing treatments for rare diseases caused by protein deficiencies. Within this focus, the company markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is developing treatments for Hunter syndrome and Gaucher disease. Outside its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene- Activated(R) erythropoietin product for anemia related to kidney disease, in the European Union. TKT was founded in 1988 and is headquartered in Cambridge, Massachusetts, with additional operations in Europe, Canada and Latin America. Additional information about TKT is available on the company's website at http://www.tktx.com/. Gene-Activated(R) is a registered trademark and Replagal(TM) is a trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of Aventis Pharmaceuticals, Inc. Contact: Daniella M. Lutz Corporate Communications Specialist (617) 349-0205 DATASOURCE: Transkaryotic Therapies, Inc. CONTACT: Daniella M. Lutz of Transkaryotic Therapies, Inc., Corporate Communications Specialist, +1-617-349-0205 Web site: http://www.tktx.com/ Company News On-Call: http://www.prnewswire.com/comp/120657.html

Copyright